Edgar Filing: KING RICHARD - Form 4

KING RICHARD Form 4							
February 13, 2012							
FORM 4 UNITED		RITIES AND EXCHANGE COMMISSION ashington, D.C. 20549				PPROVAL 3235-0287	
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							
(Print or Type Responses)							
		er Name and Ticker or Tra RX PHARMACEUTI ACRX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (C/O ACELRX PHARMACEUTICALS, INC CHESAPEAKE DRIVE	(Month/ 02/13/2	of Earliest Transaction Day/Year) 2012		_X_ Director _X_ Officer (giv below) Pre		6 Owner er (specify	
(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
REDWOOD CITY, CA 940	63			Form filed by Person	More than One R	eporting	
(City) (State)	(Zip) Tab	le I - Non-Derivative Sec	urities Ac	equired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)		3. 4. Securities TransactionAcquired (A) Code Disposed of ((Instr. 8) (Instr. 3, 4 and (A) or Code V Amount (D)	or D) d 5))	Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect	
Reminder: Report on a separate line	e for each class of sec	urities beneficially owned	directly or	indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: KING RICHARD - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	orDeri Secu Acqu Disp	5. Number of nDerivative6. Date Exercisable DateSecurities(Month/Day/Year)Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		and Expiration	7. Title and Amc Underlying Secu (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Ar Nu Sh
Common Stock (Right to Buy) (1)	\$ 3.39	02/13/2012		А		262,214	02/13/2013(2)(3)	02/12/2022	Common Stock	20

Reporting Owners

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			
KING RICHARD C/O ACELRX PHARMACEUTICALS, INC 575 CHESAPEAKE DRIVE REDWOOD CITY, CA 94063	C. X		President and CEO				
Signatures							
/s/ James Welch, Attorney-in-fact 02/12	3/2012						
**Signature of Reporting Person D	ate						

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Issued pursuant to the 2011 Equity Incentive Plan.

The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting(2) Commencement Date (February 13, 2012) and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months.

(3) The shares have double-trigger acceleration on a change of control.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.